Stoke Therapeutics amends bylaws to conform to DGCL and universal proxy rules

Stoke Therapeutics, Inc.

Updated provisions on adjournment, stockholder lists, and electronic transmission of notices to align with recent DGCL amendments.
Revised advance notice bylaws require additional disclosures, limit nominees to board seats up for election, and mandate nominee interviews.
Added rules to comply with universal proxy (Rule 14a-19): stockholders must certify compliance and provide evidence 5 business days before meeting.
Requires stockholders soliciting proxies to use a non-white proxy card; authorizes emergency bylaws for quorum issues.
Effective February 2, 2023; no financial or operational impact disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.